Racial disparities in pancreatic cancer clinical trials: Defining the problem and identifying solutions

Allison N. Martin, Rebecca A. Snyder

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Underrepresented minority patients with pancreatic cancer have differential access to cancer treatments, including clinical trials. The successful conduct and completion of clinical trials is critical to improve outcomes for patients with pancreatic cancer. Therefore, it is essential to consider how to maximize eligibility of patients for both therapeutic and non-therapeutic clinical trials. It is important for clinicians and for the health system to understand individual-, clinician-, and system-level barriers to recruitment, enrollment, and completion of clinical trials to alleviate bias. Understanding strategies that lead to improved enrollment of underrepresented minorities, socioeconomically disadvantaged individuals, and underserved communities will improve generalizability of cancer clinical trials and advance health equity.

Original languageEnglish (US)
Title of host publicationPancreatic Cancer
Subtitle of host publicationBasic Mechanisms and Therapies
EditorsLuni Emdad, Azeddine Atfi, Rajan Gogna, Jose G. Trevino, Paul B. Fisher
PublisherAcademic Press Inc.
Pages185-201
Number of pages17
ISBN (Print)9780443133541
DOIs
StatePublished - Jan 2023

Publication series

NameAdvances in Cancer Research
Volume159
ISSN (Print)0065-230X
ISSN (Electronic)2162-5557

Keywords

  • Cancer disparities
  • Clinical trials
  • Pancreas cancer
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Racial disparities in pancreatic cancer clinical trials: Defining the problem and identifying solutions'. Together they form a unique fingerprint.

Cite this